What laboratory tests and treatment options are recommended for a patient presenting with symptoms of arthritis?

Laboratory Testing for Arthritis

For any patient presenting with arthritis symptoms, order a core laboratory panel consisting of: RF, anti-CCP antibodies, CRP (preferred over ESR), complete blood count with differential, comprehensive metabolic panel (liver and renal function), and urinalysis. 1, 2

Essential First-Line Laboratory Tests

The minimal laboratory workup should include the following tests, which provide both diagnostic and prognostic information 2:

Autoantibody Testing

• Anti-cyclic citrullinated peptide (anti-CCP) antibodies: This is the most specific serological marker for rheumatoid arthritis with 90-95% specificity and 60-70% sensitivity, superior to RF for confirming diagnosis 3
• Rheumatoid factor (RF): Has lower specificity (70%) but similar sensitivity to anti-CCP and provides complementary diagnostic information 1, 3
• Both RF and anti-CCP should be ordered simultaneously at initial presentation, as they are cornerstone tests for RA diagnosis and prognosis 1

Inflammatory Markers

• C-reactive protein (CRP): Preferred over ESR as it is more reliable, not age-dependent, and provides a simple, validated, reproducible test 1
• Erythrocyte sedimentation rate (ESR): Should be measured at baseline for diagnostic and prognostic purposes 1
• Critical pearl: Do not dismiss arthritis diagnosis based on normal ESR/CRP—acute phase reactants are poor predictors and can be normal even in active inflammatory disease 1, 3

Baseline Laboratory Assessment

• Complete blood count with differential: Identifies systemic inflammation, assesses for cytopenias before starting treatment, and calculates neutrophil-to-lymphocyte ratio 1, 2
• Comprehensive metabolic panel: Including liver function tests (transaminases), renal function, glucose, and urate levels for baseline assessment and monitoring 1, 2
• Urinalysis: Part of standard initial workup to identify renal involvement and rule out other conditions 1, 2

Conditional Testing Based on Clinical Features

When Diagnosis Remains Uncertain

• Antinuclear antibodies (ANA): Order if diagnosis remains uncertain after initial workup to screen for other connective tissue diseases like systemic lupus erythematosus 1, 2, 3
• ANA has 95% sensitivity for screening autoimmune conditions 2

When Spondyloarthropathy is Suspected

• HLA-B27 typing: Order if symptoms suggest reactive arthritis, affect the spine, or if spondyloarthropathy is suspected based on axial or entheseal involvement 1, 2, 3

Pre-Treatment Screening (Before Biologics)

• Hepatitis B, Hepatitis C, and tuberculosis screening: Required before starting any biologic therapy 1

Baseline Imaging Studies

• Plain radiographs: Obtain bilateral hand, wrist, and foot X-rays at initial presentation to assess for erosions, which are highly predictive for RA diagnosis and disease persistence 1
• Repeat X-rays at 6 months and 12 months to monitor radiographic progression 1

Monitoring After Diagnosis

Serial Laboratory Testing

• Repeat CRP and ESR every 4-6 weeks after treatment initiation to monitor disease activity and treatment response 1, 3
• Serial inflammatory markers guide treatment escalation but should not be the sole determinant of treatment decisions 3

Disease Activity Assessment

• Use composite disease activity measures (SDAI or CDAI) at each visit, incorporating CRP when elevated 1
• SDAI is preferred over DAS28 when CRP is elevated, as it provides more stringent disease activity assessment 1

Critical Pitfalls to Avoid

• Seronegative RA accounts for 20-30% of cases—negative RF and anti-CCP do not exclude inflammatory arthritis 1, 3
• Do not delay treatment waiting for positive serology—early aggressive therapy prevents irreversible joint damage, and seronegative RA has similar prognosis to seropositive disease 1
• Do not rely solely on laboratory tests without thorough clinical examination, as this can lead to misdiagnosis in 20-30% of cases 2
• Refer to rheumatology within 6 weeks if inflammatory arthritis is suspected, regardless of autoantibody results, as early specialist evaluation improves outcomes 3

Treatment Considerations After Laboratory Confirmation

Once inflammatory arthritis is confirmed, start methotrexate 15 mg weekly as first-line DMARD immediately, without delaying for complete serologic workup. 1

Methotrexate Monitoring Requirements

• Liver function tests should be performed at baseline and at 4-8 week intervals 4
• Monitor for hematologic toxicity: leukopenia (WBC <3000/mm³), thrombocytopenia (platelets <100,000/mm³), and pancytopenia 4
• Stop methotrexate immediately if there is a significant drop in blood counts 4

Treatment Targets

• Target remission (SDAI ≤3.3) or low disease activity (SDAI ≤11) 1
• If inadequate response after 3 months of methotrexate, consider triple DMARD therapy or adding a biologic agent such as a TNF inhibitor 1